AC Immune raises $22m, initiates world's first anti-pTau Alzheimer's vaccine trial
This article was originally published in Scrip
Executive Summary
Swiss-based biopharmaceutical firm AC Immune has secured CHF20m (approximately $22m) in series D funding to continue development of its pipeline of Alzheimer's therapies, including phospho-Tau targeting vaccine candidate ACI-35.